Method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)

Abstract

A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).

What is claimed is: 
     
         1 . A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV), comprising administering to a subject in need thereof:
 (a) an anti-C5 agent and (b) a VEGF antagonist,   wherein (a) and (b) are administered in an amount that is effective for treating or preventing IPCV, and   wherein the administering occurs for a first administration period induction phase followed by a second administration period maintenance phase wherein only the anti-C5 agent is administered monthly throughout the maintenance phase.   
     
     
         2 . The method of  claim 1  wherein the administering occurs once every month,±about seven days, for a first administration period of at least three consecutive months, said first administration period comprises administration of (a) and (b) on the same day followed by administration of a subsequent dose of (a) after about 14 days. 
     
     
         3 . The method of  claim 2  wherein (a) and (b) are administered for a second administration period after completion of said first administration period, wherein (a) is administered at least once every month during said second administration period and (b) is administered once every other month together with administration of (a) during said second administration period. 
     
     
         4 . The method of  claim 1  wherein (a) is administered after (b) during said first administration period. 
     
     
         5 . The method of  claim 3  wherein an additional dose of (a) is administered during said second administration period on months when (a) and (b) are both administered. 
     
     
         6 . The method of  claim 5  wherein said additional dose of (a) is administered about 48 hours before administering (a) and (b) on the same day. 
     
     
         7 . The method of  claim 3  wherein (a) and (b) are administered on the same day during the second administration period. 
     
     
         8 . The method of  claim 1  wherein the antiC5 agent is avacincaptad pegol or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 8  wherein administering avacincaptad pegol or another pharmaceutically acceptable salt thereof is intravitreally and in an amount of about 2.0 mg/eye. 
     
     
         10 . The method of  claim 3  wherein avacincaptad pegol is administered intravitreally in an amount of 4.0 mg/eye once every month when (b) is not administered. 
     
     
         11 . The method of  claim 3 , wherein the second administration period begins about a month after the day of the last month of the first administration period. 
     
     
         12 . The method of  claim 3 , wherein the antiC5 agent is avacincaptad pegol or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The method of  claim 12  wherein administering avacincaptad pegol or another pharmaceutically acceptable salt thereof is intravitreally and in an amount of about 2.0 mg/eye. 
     
     
         14 . The method of  claim 13  wherein the VEGF antagonist is ranibizumab, bevacizumab, pegaptanib sodium, tivozanib, ESBA1008 or aflibercept. 
     
     
         15 . The method of  claim 14  wherein administering the VEGF antagonist is intravitreally. 
     
     
         16 . The method of  claim 15  wherein the VEGF antagonist is aflibercept and is administered in an amount of about 2 mg/eye, bevacizumab and is administered in an amount of about 1.25 mg/eye, or ranibizumab and is administered in an amount of about 0.5 mg/eye. 
     
     
         17 . The method of  claim 16  wherein the VEGF antagonist is aflibercept and is administered in an amount of about 2 mg/eye. 
     
     
         18 . The method of  claim 17  wherein avacincaptad pegol is administered intravitreally in an amount of 4.0 mg/eye once every month when (b) is not administered. 
     
     
         19 . The method of  claim 17  wherein avacincaptad pegol is administered after aflibercept during said first administration period. 
     
     
         20 . The method of  claim 19  wherein an additional dose of avacincaptad pegol is administered during said second administration period on months when avacincaptad pegol and aflibercept are both administered. 
     
     
         21 . The method of  claim 1  wherein the anti-C5 agent comprises the compound having the structure below: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, where Aptamer=fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO: 1) 
         wherein fC and fU=2′-fluoro nucleotides, and mG and mA=2′-OMe nucleotides and all other nucleotides are 2′-OH and where 3T indicates and inverted deoxy thymidine.